There is considerable debate about the choice of intravenous platelet glycoprotein IIb/IIIa inhibitors for percutaneous coronary intervention, after a meta-analysis of 7 trials and 16,770 patients has shown a 38% reduction in death or non-fatal MI 30 days after the index procedure. At 149 hospitals in 18 countries throughout North America, Europe and Australia, 4810 patients were randomized between 12/30/99 and 8/25/00 and treated with either tirofiban or abciximab on a double-blind, double dummy basis. Clopidogrel and aspirin were administered preprocedurally, along with a 70 U/kg intravenous heparin bolus. The dose of tirofiban was 10 mcg/kg bolus and 0.15 mcg/kg/min infusion for 18 -24 hrs; for abciximab it was 0.25 mcg/kg bolus and 0.125 mcg/kg/min (max 10 mcg/min) infusion. Patients qualified by having suitable anatomy for "intent-to-stent" lesions addressed by percutaneous revascularization, and were not with evolving ST-elevation MI or with serum creatinine Ͼ2.5 mg/dl. The primary endpoint is 30 death or non-fatal MI and the trial has Ͼ80% power to determine non-inferiority for tirofiban with an expected event rate in the control (abciximab) group of 5.3% based on the EPISTENT trial. The primary endpoint data will be presented along with the key subgroups such as diabetics. Follow-up data for the trial to 1 year will also be performed.
To determine whether hematopoietic stem cells (HSC) can transform into cardiomyocytes with the potential to repair dead myocardium after infarction, Lin/c-kit I-II HSC were harvested from transgenic mice expressing green fluorescent protein (GFP) and injected in the region bordering the infarct, 3-5 hours after coronary artery occlusion in mice. A band of closely packed cells was identified 7 to 17 days later in nearly 50% of HSC injected hearts, between the endocardial and epicardial surface of the infarcted ventricle. This band occupied 50 75% of the damaged portion of the wall. c-kit/GFP positive HSC were found in the infarcted area shortly after coronary ligation and were still detectable at 7 days. c-kit stained HSC were not labeled by markers of myocytes, ␣-sarcomeric actin and myosin, endothelial cells, factor VIII, and smooth muscle cells, smooth muscle actin. The band of tissue included in the infarcted zone was constituted 75% by GFP, ␣-sarcomeric actin, myosin and ␣-actinin positive cardiac muscle cells. Other GFP-positive cell populations were endothelial cells and smooth muscle cells, organized in nascent capillary structures and arterioles. Proliferating myocytes were small with partially aligned myofibrils and resembled late fetal-neonatal cells. GFP-positive replicating myocytes, endothelial cells and smooth muscle cells were c-kit negative. Infarcted mice were injected with BrdU, once a day for 4 days, to establish the extent of cell proliferation in the regenerating myocardium: 28% myocytes, 17% endothelial cells and 12% smooth muscle cells were BrdU positive. These three levels of BrdU labeling were statistically different. Additionally, the percentages of cells positive to Ki67 were measured to evaluate the fraction of cycling cells at this stage of repair: 18% myocytes, 10% endothelial cells and 8% smooth muscle cells were in G 1 -G 2 M. In conclusion, HSC, when injected in the heart, rapidly differentiate into myocardium resulting in significant recovery of muscle mass after infarction. Cardiac myxomas arise from primitive pluripotent mesenchymal cells within the subendocardium. In autosomal dominant Carney complex, intracardiac myxomas develop in the setting of lentiginosis and endocrinopathy. We previously localized the Carney complex gene defect to human chromosome 17q24. We now demonstrate that mutations in the chromosome 17 PRKAR1␣ gene encoding the R1␣ regulatory subunit of cAMP-dependent protein kinase A (PKA) cause inherited cardiac myxomas and Carney complex. We detect heterozygous deletions in the PRKAR1␣ gene in three unrelated kindreds (⌬FSterGly208 in Family YA, ⌬FSterVal253 in Family YB, ⌬FsterThr163 in Family YF). These mutations were confirmed by bidirectional sequence analysis and by denaturing acrylamide gel electrophoresis. Each mutant produces a frameshift and premature stop codon with consequent PRKAR1␣ haploinsufficiency. DNA and protein analysis of an atrial myxoma resected from an affected individual in Family YA reveals that the tumor cells retain both the wildtype and mutant PRKAR1␣ alleles, and that wildtype R1␣ but not mutant protein is stably expressed. However, western blot analysis demonstrates a reversal of the ratio of PKA regulatory subunits R1␣ to R1␤ in the myxoma that can alter PKA activity and contribute to tumor development. Our data, then, suggest that PRKAR1␣ acts as a tumor suppressor gene in the heart via regulation of PKA activity. These novel findings implicate the cAMP-dependent PKA signaling pathway as a critical modulator of cardiac cell growth and differentiation. Further research into the specific role of PKA in the heart may ultimately foster new therapeutic strategies for cardiac cell regeneration.
Mutations in the R1␣

Functional Proteomic Analysis of Protein Kinase C Signaling Complexes in Preconditioning.
Peipei Ping, Jun Zhang, Roberto Bolli, Cardiology Division, University of Louisville, KY.
Studies from our laboratory and others have shown that transgenic (Tg) mice expressing low levels of active protein kinase C (PKC) exhibit resistance to ischemic injury, a cardioprotected phenotype analogous to that observed during preconditioning. Although PKC has been shown to activate multiple downstream targets in preconditioning, the molecular components that form PKC signaling complexes and those that constitute the PKC signaling architecture are unknown. We used a proteomic approach to characterize PKC signaling complexes. PKC monoclonal antibodies were used to immunoprecipitate cardiac tissues from PKC Tg mice and wild type mice (nϭ10 each). Combining 2-D electrophoresis, MALDI mass spectrometry, and immunoblotting, so far we have identified 27 known and 12 unknown molecules in PKC signaling complexes. These include signaling proteins (RACK2, Lck, Src, Pyk2, PI3 kinase (p170/p85), p38 MAPK, p54/p46 JNKs, ERKs, Hsp27/Hsp71, ␣B-crystallin, iNOS, eNOS), and structural proteins (cardiac ␣-actin, troponin T, ␣-tropomyosin, prohibitin, desmin, Lap2, caveolin-3). Many of these proteins were not previously suspected to be in PKC immunocomplexes. In PKC Tg mice, altered expression and post-translational modification were evident in at least 21 known and 10 uncharacterized molecules. These data show, for the first time, (i) that PKCe forms signaling complexes with multiple proteins in multiple subcellular compartments, suggesting heretofore-unrecognized functions of PKC isozyme; and (ii) that cardioprotection is coupled with dynamic modulation of PKC-associated proteins and recruitment of signaling molecules to PKC complexes. Functional proteomic analysis of PKC signaling complexes is a crucial step toward understanding PKC-dependent signaling architecture and cardioprotection.
Mutations in the Human ␦-Sarcoglycan Gene in Familial and Sporadic Dilated Cardiomyopathy, a Disease of the Cytoskeleton and Sarcolemma
Tsubata S, Bowles KR, Vatta M, Zintz C, Bowles NE, Towbin JA, Pediatric Cardiology, Baylor College of Medicine, Houston, TX Background: Dilated cardiomyopathy (DCM) is a significant cause of morbidity and mortality due to congestive heart failure and rhythm abnormalities. Approximately 30% of cases are familial (FDCM), with the remainder appearing sporadically. Autosomal dominant inheritance is the most common form of FDCM, although X-linked disease is also well described. Two genes have been identified for the X-linked forms (dystrophin and tafazzin), whereas three genes have been identified in autosomal dominant FDCM (actin, lamin A/C, desmin). We have hypothesized that DCM is a disease of the cytoskeleton and sarcolemma and have focused our studies on candidate genes whose products are found in these structures. Here we report the screening of ␦-sarcoglycan, a member of the dystrophin-associated protein complex (DAPC). Methods: Blood was drawn and DNA extracted from one 4-generation family and 50 sporadic cases of DCM after informed consent. Myocardial samples were obtained after transplantation or autopsy. The ␦-sarcoglycan gene was screened for mutations using single strand conformation polymorphism (SSCP), denaturing high performance liquid chromatography (CHPLC), and DNA sequencing. Protein structural analysis and immunohistochemistry were performed. Results: Mutation analysis of the FDCM pedigree identified a single nucleotide change in exon 6 of ␦-sarcoglycan causing an amino acid change from a polar (serine) to nonpolar amino acid (alanine) altering the protein secondary structure. In 2 of the 50 sporadic cases, a 3bp deletion in exon 9, which deletes lysine at position 238, occurred. Neither the missense mutation nor deletion mutation was seen in 200 control patients. Immunohistochemistry demonstrated significant reduction of ␦-sarcoglycan staining. Conclusions: Mutation of the ␦-sarcoglycan gene causes autosomal dominant FDCM. As mutations of this gene are also known to cause the Syrian hamster cardiomyopathy as well as human limb girdle muscular dystrophy, it appears that mutations in this gene place patients at risk for a spectrum of clinical features ranging from cardiomyopathy to skeletal myopathy. This is similar to other DAPC members and dystrophin itself, supporting our final common pathway hypothesis which suggests that DCM results from disruption of the cytoskeleton/sarcolemma,
Dual Modulation of Cell Survival and Cell Death by ␤2-Adrenergic Gi and Gs Signaling in Adult Mouse Cardiac Myocytes
Wei-Zhong Zhu, Ming Zheng, Brian Kobilka*, Rui-Ping Xiao, Laboratory of Cardiovascular Science, GRC, NIA, NIH, Baltimore, N4D 21224;*Howard Hughcs Medical Institute, Stanford Univ Med Cent, Stanford, CA 94305.
Cardiac ␤2-AR activates both Gs and Gi proteins whereas ␤1-AR couples only to Gs. The goal of this study is to determine whether ␤1-AR and ␤2-AR differ in regulating cardiomyocyte survival and apoptosis, if so, to explore underlying mechanisms. To avoid complicated crosstalks between ␤-AR subtypes, we express ␤1-AR or ␤2-AR individually in the null background of ␤1 ␤2 double knockout mouse cardiomyocytes using adult mouse myocyte culture and adenoviral gene transfer techniques. Stimulation of ␤1-AR, but not ␤2-AR. markedly induces myocyte apoptosis, as indicated by increased TUNEL or Hoechst staining positive cells and DNA fragmentation. Inhibition Gi signaling with pertussis toxin converts ␤2-AR to ␤1-AR in terms of its apoptotic effect, suggesting that Gi is essential for ␤2-AR-mediated survival effect. To explore the downstream signaling events of ␤2-AR-coupled Gi, we first examined the possible involvement of p38 MAPK, since recent studies propose that p38 MAPK underlies Gi-dependent anti-apoptotic effects. We found that although stimulation of either ␤-AR subtype increases p38 MAPK activity, this effect is insensitive to PTX, excluding a role of p38 MAPK in ␤2-AR-mediated cell-survival. In contrast, ␤2-AR (but not ␤1-AR) elevates the activity of Akt, a powerful survival signal; this effect is fully abolished by inhibiting Gi with pertussis toxin, scavenging G␤␥ with ␤ARK-ct, or blocking PI3K with LY294002, indicating that ␤2-AR activates Akt via Gi␤␥-PI3K pathway. Most importantly, inhibition of the Gi␤␥-PI3K-Akt pathway converts ␤2-AR signaling from survival to apoptotic. Thus, ␤2-AR, unlike ␤1-AR, activates concurrent apoptotic and survival signals in cardiomyocytes, and the survival effect is mediated by the Gi␤␥-PI3K-Akt pathway. The strikingly different effects of ␤-AR subtypes on cardiac cell survival and apoptosis may have important pathophysiological and therapeutic implications in chronic heart failure.
